Low dentin matrix protein 1 expression correlates with skeletal metastases development in breast cancer patients and enhances cell migratory capacity in vitro
Bucciarelli, E.; Sidoni, A.; Bellezza, G.et al.
2007 • In Breast Cancer Research and Treatment, 105 (1), p. 95-104
dentin matrix protein 1; breast cancer; skeletal metastases; migration; breast cancer cell lines; prognosis
Abstract :
[en] Small integrin-binding ligand N-linked glycoproteins (SIBLINGs) constitute a family of extracellular matrix proteins involved in bone homeostasis. Their pattern of expression has been primarily reported in bone and tooth and, more recently, in several cancer types. Dentin matrix protein 1 (DMP1), a SIBLING family member, expression was investigated by immunohistochemistry in a retrospective series of 148 primary human breast cancers. Correlations between DMP1 expression levels in the tumors and clinicopathologic features, bone metastases development and relapse of the disease were examined. DMP1 was expressed by 63.5% of the breast tumors analyzed. Significant inverse associations were found between DMP1 expression levels and the size and grade of the tumors (both, P < 0.0001). High DMP1 expression levels in the primary breast lesions were associated with a lower risk of subsequent development of skeletal metastases (P = 0.009). Patients with tumors expressing high levels of DMP1 had a significantly higher disease-free survival rate than those with low DMP1-expressing tumors (P = 0.0062). When DMP1 expression was examined in breast cancer cell lines, we found that non invasive MCF-7 and T47-D cells expressed higher levels than highly invasive MDA-MB-231 and Hs578T cells. Moreover, the specific inhibition of DMP1 expression in MCF-7 cells using siRNAs promoted significantly their migratory capability. Our data implicate for the first time DMP1 expression in breast cancer progression and bone metastases development.
Castronovo, Vincenzo ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie générale et cellulaire
Bellahcene, Akeila ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Labo de recherche sur les métastases
Language :
English
Title :
Low dentin matrix protein 1 expression correlates with skeletal metastases development in breast cancer patients and enhances cell migratory capacity in vitro
Publication date :
September 2007
Journal title :
Breast Cancer Research and Treatment
ISSN :
0167-6806
eISSN :
1573-7217
Publisher :
Springer, New York, United States - New York
Volume :
105
Issue :
1
Pages :
95-104
Peer reviewed :
Peer Reviewed verified by ORBi
Name of the research project :
Inter-University Attraction Pole (IAP-P5/31) METABRE
Funders :
Fondazione Cassa Risparmio Perugia F.R.S.-FNRS - Fonds de la Recherche Scientifique ULiège FSR - Université de Liège. Fonds spéciaux pour la recherche EC - European Commission
Fisher LW, Fedarko NS (2003) Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res 44:33-40
Brown LF, Berse B, Van De Water L, Papadopoulos-Sergiou A, Peruzzi CA, Manseau EJ, Dvorak HF, Senger DR (1992) Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Biol Cell 3:1169-1180
Brown LF, Papadopoulos SA, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR (1994) Osteopontin expression and distribution in human carcinomas. Am J Pathol 145:610-623
Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10:184-190
Rittling SR, Chambers AF (2004) Role of osteopontin in tumour progression. Br J Cancer 90:1877-1881
Bellahcène A, Merville M-P, Castronovo V (1994) Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res 54:2823-2826
Waltregny D, Bellahcène A, Van Riet I, Fisher LW, Young M, Fernandez P, Dewé W, de Leval J, Castronovo V (1998) Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Nat Cancer Inst 90:1000-1008
Bellahcène A, Albert V, Basolo F, Pollina L, Fisher LW, Castronovo V (1998) Ectopic expression of bone sialoprotein in thyroid human cancer. Thyroid 8:637-641
Bellahcène A, Maloujahmoum N, Fisher LW, Pastorino H, Tagliabue E, Ménard S, Castronovo V (1997) Expression of bone sialoprotein in human lung cancer. Calcif Tissue Int 61:183-188
Detry C, Waltregny D, Quatresooz P, Chaplet M, Kedzia W, Castronovo V, Delvenne P, Bellahcene A (2003) Detection of bone sialoprotein in human (pre)neoplastic lesions of the uterine cervix. Calcif Tissue Int 73:9-14
Bellahcène A, Van Riet I, de Greef C, Antoine N, Young MF, Van Camp B, Castronovo V (2000) Bone sialoprotein mRNA and protein expression in human multiple myeloma cell lines and patients. Br J Haematol 111:1118-1121
Bellahcène A, Kroll M, Liebens F, Castronovo V (1996) Bone sialoprotein detection in human breast cancer cells: a potential predictor of bone metastases. J Bone Min Res 11:665-670
Bellahcène A, Menard S, Bufalino R, Moreau L, Castronovo V (1996) Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 69:350-353
Waltregny D, Bellahcène A, de Leval X, Florkin B, Weidle U, Castronovo V (2000) Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res 15:834-843
Chaplet M, Waltregny D, Detry C, Fisher LW, Castronovo V, Bellahcène A (2006) Expression of dentin sialophosphoprotein in human prostate cancer and its correlation with tumor aggressiveness. Int J Cancer 118:850-856
Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, Oudet CL (2000) MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67:54-68
Ogbureke KU, Fisher LW (2004) Expression of SIBLINGs and their partner MMPs in salivary glands. J Dent Res 83:664-670
Ogbureke KU, Fisher LW (2005) Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs). Kidney Int 68:155-166
Chaplet M, De Leval L, Waltregny D, Detry C, Fornaciari G, Bevilacqua G, Fisher LW, Castronovo V, Bellahcène A (2003) Dentin matrix protein 1 is expressed in human lung cancer. J Bone Miner Res 18:1506-1512
Fisher LW, Jain A, Tayback M, Fedarko NS (2004) Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers. Clin Cancer Res 10:8501-8511
World Health Organization (1982) Histological typing of breast tumors. Tumori 68:181-198
Elston C, Ellis I (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long term follow-up. Histopathology 19:403-410
Jain A, Karadag A, Fohr B, Fisher LW, Fedarko NS (2002) Three SIBLINGs (small integrin-binding ligand, N-linked glycoproteins) enhance factor H's cofactor activity enabling MCP-like cellular evasion of complement-mediated attack. J Biol Chem 277:13700-13708
Chaplet M, Detry C, Deroanne C, Fisher LW, Castronovo V, Bellahcene A (2004) Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition. Biochem J 384:591-598
Diel IJ, Solomayer EF, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan C, Pecherstorfer M, Conradi R, Kehr G, Boehm E, Armbruster FP, Bastert G (1999) Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 5:3914-3919
Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7:4060-4066
Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62:3417-3427
Donati V, Boldrini L, Dell'Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G (2005) Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 11:6459-6465
Fedarko NS, Fohr B, Fisher LW (2000) DMP-1 inactivates complement by bridging Factor H to cell surface receptors. J Dent Res 79:339
Bellahcène A, Bonjean K, Fohr B, Fedarko NS, Robey FA, Young MF, Fisher LW, Castronovo V (2000) Bone sialoprotein mediates human endothelial cell attachment and migration and promotes angiogenesis. Circ Res 86:885-891
Leali D, Dell'Era P, Stabile H, Sennino B, Chambers AF, Naldini A, Sozzani S, Nico B, Ribatti D, Presta M (2003) Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J Immunol 171:1085-1093
Hirama M, Takahashi F, Takahashi K, Akutagawa S, Shimizu K, Soma S, Shimanuki Y, Nishio K, Fukuchi Y (2003) Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett 198:107-117
Fedarko NS, Jain A, Karadag A, Fisher LW (2004) Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. Faseb J 18:734-736
Karadag A, Fedarko NS, Fisher LW (2005) Dentin matrix protein 1 enhances invasion potential of colon cancer cells by bridging matrix metalloproteinase-9 to integrins and CD44. Cancer Res 65:11545-11552
Karadag A, Ogbureke KU, Fedarko NS, Fisher LW (2004) Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. J Natl Cancer Inst 96:956-965
Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174
Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T, Talieri M (2001) Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer 84:1488-1496
Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM (2004) Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 10:7621-7628
Remacle AG, Noel A, Duggan C, McDermott E, O'Higgins N, Foidart JM, Duffy MJ (1998) Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer 77:926-931
Talvensaari-Mattila A, Turpeenniemi-Hujanen T (2005) Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma. Cancer Lett 217:237-242
Diaz LK, Zhou X, Wright ET, Cristofanilli M, Smith T, Yang Y, Sneige N, Sahin A, Gilcrease MZ (2005) CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res 11:3309-3314